Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H6O2S |
| Molecular Weight | 154.186 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(S)C=CC=C1
InChI
InChIKey=NBOMNTLFRHMDEZ-UHFFFAOYSA-N
InChI=1S/C7H6O2S/c8-7(9)5-3-1-2-4-6(5)10/h1-4,10H,(H,8,9)
Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Primary | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytotoxicity of Triorganophosphinegold(I) n-Mercaptobenzoates, n = 2, 3 and 4. | 2002 |
|
| Preconcentration of lead with Amberlite XAD-2 and Amberlite XAD-7 based chelating resins for its determination by flame atomic absorption spectrometry. | 2002 Mar 11 |
|
| Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres. | 2004 Apr 1 |
|
| One-pot synthesis of benzo[e]1,4-oxathiepin-5-ones under solvent-free condition via self-promoted thiolysis of 1,2-epoxides. | 2004 Dec 10 |
|
| Development of a direct-binding chloramphenicol sensor based on thiol or sulfide mediated self-assembled antibody monolayers. | 2004 Feb 15 |
|
| A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). | 2004 Jul |
|
| Using model complexes to augment and advance metalloproteinase inhibitor design. | 2004 May 17 |
|
| Determination of thiocyl in biological samples by liquid chromatography with ThioGlo 3 derivatization. | 2004 Oct 5 |
|
| Self-assembly of dialkyltin moieties and mercaptobenzoic acid into macrocyclic complexes with hydrophobic "pseudo-cage" or double-cavity structures: supramolecular infrastructures involving intermolecular C-H...S weak hydrogen bonds and pi-pi interactions. | 2005 Dec 23 |
|
| Quantitative description of the deactivation channels of the first excited singlet state of 2- and 4-thiosalicylic acids. | 2005 Jul 28 |
|
| Chelating sorbents based on silica gel and their application in atomic spectrometry. | 2005 Mar |
|
| Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method. | 2005 Sep 1 |
|
| Effect of ring substitution position on the structural conformation of mercaptobenzoic acid self-assembled monolayers on Au(111). | 2006 Dec 19 |
|
| Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal. | 2006 Jul |
|
| Analysis of acrylamide in food samples by capillary zone electrophoresis. | 2006 Jul 7 |
|
| Thimerosal induces apoptosis and G2/M phase arrest in human leukemia cells. | 2006 Sep |
|
| Analysis of acrylamide in food products by in-line preconcentration capillary zone electrophoresis. | 2006 Sep 29 |
|
| Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans. | 2007 |
|
| Competing ligand exchange-solid phase extraction method for the determination of the complexation of dissolved inorganic mercury (II) in natural waters. | 2007 Aug 29 |
|
| Field amplified sample injection-capillary electrophoresis-tandem mass spectrometry for the analysis of acrylamide in foodstuffs. | 2007 Aug 3 |
|
| Heterocycles [h]fused onto 4-oxoquinoline-3-carboxylic acid, part IV. Convenient synthesis of substituted hexahydro [1,4]thiazepino[2,3-h]quinoline-9-carboxylic acid and its tetrahydroquino[7,8-b]benzothiazepine homolog. | 2007 Jul 27 |
|
| Relationship between redox activity and chemical speciation of size-fractionated particulate matter. | 2007 Jun 7 |
|
| In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols. | 2008 Apr 30 |
|
| Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. | 2008 Aug |
|
| Determination of acrylamide during roasting of coffee. | 2008 Aug 13 |
|
| Development of a stable isotope dilution assay for the quantitation of glycidamide and its application to foods and model systems. | 2008 Aug 13 |
|
| Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. | 2008 Jan 10 |
|
| Synthesis and biological evaluation of sulfur-containing cinnamate and salicylate derivatives. | 2008 Mar |
|
| Removal of malodorous organic sulfides with molecular oxygen and visible light over metal phthalocyanine. | 2008 Mar 21 |
|
| Thimerosal and the relevance of patch-test reactions in children. | 2008 Sep-Oct |
|
| Zinc ions cause the thimerosal-induced signal of fluorescent calcium probes in lymphocytes. | 2009 Feb |
|
| [1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate. | 2009 Jan 8 |
|
| The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. | 2009 Jul |
|
| Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites. | 2009 Jun 30 |
|
| Ultrasonic-assisted precolumn derivatization-HPLC determination of acrylamide formed in Radix Asparagi during heating process. | 2009 May 1 |
|
| Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children. | 2009 Oct 27 |
|
| Synthesis and characterization of thiosalicylic acid stabilized gold nanoparticles. | 2009 Sep 15 |
|
| 2-[(2-Carboxy-phen-yl)sulfan-yl]acetic acid. | 2009 Sep 5 |
|
| Field-assisted synthesis of SERS-active silver nanoparticles using conducting polymers. | 2010 Aug |
|
| Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. | 2010 Jan |
|
| Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. | 2010 Jul |
|
| Intercalation of anionic organic ultraviolet ray absorbers into layered zinc hydroxide nitrate. | 2010 Jul 1 |
|
| Sensitization effect of thimerosal is mediated in vitro via reactive oxygen species and calcium signaling. | 2010 Jul-Aug |
|
| Electrochemical scanning tunneling spectroscopy of redox-active molecules bound by Au-C bonds. | 2010 Mar 3 |
|
| Poly[(dimethyl-formamide)(μ(4)-2,2'-sulfanediyldibenzoato)nickel(II)]. | 2010 Mar 6 |
|
| 2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2). | 2010 May 26 |
|
| Ultraviolet treatment and biodegradation of dibenzothiophene: Identification and toxicity of products. | 2010 Nov |
|
| 14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine. | 2010 Nov 6 |
|
| Low molecular weight thiols reduce thimerosal neurotoxicity in vitro: modulation by proteins. | 2010 Oct 29 |
|
| Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. | 2010 Oct-Dec |
Sample Use Guides
Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EPA PESTICIDE CODE |
78903
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
660640
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
THIOSALICYLIC ACID
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
C441201
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
2184
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
5443
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
322165
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
DTXSID4049032
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
59124
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
91099
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
ALTERNATIVE | |||
|
CIP6LXN5XW
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
59127
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
m10783
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
147-93-3
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
2739
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
DB14026
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
C87327
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
100000183747
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
205-704-3
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
